Clinical Profile and Treatment Outcome of Older (>75 years) Patients With Systemic AL Amyloidosis | oneAMYLOIDOSISvoice
Scientific Articles

Clinical Profile and Treatment Outcome of Older (>75 years) Patients With Systemic AL Amyloidosis

key information

source: Haematologica

year: 2015

authors: Sachchithanantham S, Offer M, Venner C, Mahmood SA, Foard D, Rannigan L, Lane T, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD

summary/abstract:

Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty may compound morbidity and mortality. We report the outcomes of 295 patients with systemic AL amyloidosis >=75 years seen at the UK National Amyloidosis Centre from 2005-2012. The median age was 78.5 years. The median overall survival was 20 months. Two hundred and thirty-eight patients received chemotherapy and 57 elected for supportive care only (overall survival – 24 and 8.4 months, respectively).

On intention-to-treat analysis, 44% achieved a hematologic response including a very good partial response or better in 23%. The median overall survival was 6.2 years in patients achieving very good partial response or better at the 6-month landmark analysis and 1.5 years in non-responders. Factors independently indicating a poor prognosis were: cardiac involvement, performance status  >= 2; systolic blood pressure <100 mmHg and, on landmark analysis, achieving less than a very good partial response.

Treatment of systemic AL amyloidosis in the elderly is challenging. Deep clonal responses are associated with excellent survival and organ responses. Achieving a response to the first-line regimen appears particularly important as outcomes of non-responders are similar to those of untreated patients. Prospective trials with lower toxicity, outpatient treatment regimens are needed.

organization: University College London, UK; Cross Cancer Institute, Canada; Heatherwood and Wexham Park Hospitals, UK

DOI: 10.3324/haematol.2015.128025

read more full text source

rareRelated

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close